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Abstract
The binding of bacteria to human platelets is a likely central mechanism in the pathogenesis of infective endocarditis. We
have previously found that platelet binding by Streptococcus mitis SF100 is mediated by surface components encoded by
a lysogenic bacteriophage, SM1. We now demonstrate that SM1-encoded lysin contributes to platelet binding via its direct
interaction with fibrinogen. Far Western blotting of platelets revealed that fibrinogen was the major membrane-
associated protein bound by lysin. Analysis of lysin binding with purified fibrinogen in vitro confirmed that these proteins
could bind directly, and that this interaction was both saturable and inhibitable. Lysin bound both the Aa and Bb chains
of fibrinogen, but not the c subunit. Binding of lysin to the Bb chain was further localized to a region within the fibrinogen
D fragment. Disruption of the SF100 lysin gene resulted in an 8363.1% reduction (mean 6 SD) in binding to immobilized
fibrinogen by this mutant strain (PS1006). Preincubation of this isogenic mutant with purified lysin restored fibrinogen
binding to wild type levels. When tested in a co-infection model of endocarditis, loss of lysin expression resulted in a
significant reduction in virulence, as measured by achievable bacterial densities (CFU/g) within vegetations, kidneys, and
spleens. These results indicate that bacteriophage-encoded lysin is a multifunctional protein, representing a new class of
fibrinogen-binding proteins. Lysin appears to be cell wall-associated through its interaction with choline. Once on the
bacterial surface, lysin can bind fibrinogen directly, which appears to be an important interaction for the pathogenesis of
endocarditis.
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Introduction
The pathogenesis of infective endocarditis is a complex process,
involving numerous host-pathogen interactions [1,2]. A key
interaction for disease establishment and progression is the
binding of microbes to human components, including platelets,
fibrinogen, fibrin, and fibronectin [3,4,5,6,7,8]. Although this
binding appears to be a central requirement for virulence, only a
limited number of endocarditis-related adhesins has been
identified [7,8,9].
Among the viridans group streptococci, Streptococcus mitis is a
leading cause of endovascular infection [10,11,12,13,14]. Despite its
increasing importance as a human pathogen, relatively little is known
about the virulence determinants of this organism, particularly with
regard to its interaction with platelets or other host components. Our
previous studies identified two surface proteins (PblA and PblB)
encoded by a lysogenic bacteriophage (SM1) that mediate the
binding of S. mitis to human platelets, through their interaction with
the membrane ganglioside GD3 [15,16,17]. Disruption of the genes
encoding PblA and PblB results in a significant decrease in platelet
binding in vitro, as well as a marked reduction in virulence, as
measured by an animal model of endocarditis [16,17].
Expression of these proteins on the bacterial surface is
dependent upon the activities of phage holin and lysin, which
permeabilize the cell envelope, thereby permitting the transport of
PblA and PblB to the cell wall, where they attach to phosphocho-
line (PC) residues [16]. Of note, disruption of the gene encoding
lysin (lys) resulted in a profound reduction in platelet binding, to
levels that were significantly lower than those seen with either the
parent strain, or a pblA/plbB double knock-out mutant [16]. These
findings suggested that lysin mediates platelet binding in part
through a mechanism independent of its role in the export of PblA
and PblB.
For these reasons, we investigated the mechanisms by which
lysin mediates binding to platelets, and whether this interaction
contributes to the pathogenesis of streptococcal endocarditis. Our
studies indicate that phage lysin can be localized on the bacterial
surface through its interaction with PC residues. Surface-bound
lysin can subsequently bind both free and platelet-associated
fibrinogen, through its specific interaction with the Aa and Bb
chains of the protein. Loss of lysin expression is associated with
reduced virulence in the setting of endocarditis, indicating that the
binding of lysin to fibrinogen is an important factor in the
pathogenesis of this infection.
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Characterization of lysinSM1 from bacteriophage SM1
Using the NCBI Conserved Domain Database (CDD) search
system [18], bioinformatic analysis of the predicted amino acid
sequence of lysinSM1 (Accession number Q9AF60), revealed that
an amidase-5 domain (Pfam05382; amino acids 4–146) is present
at the amino terminus, and a putative choline-binding domain is
found at the carboxyl terminus (COG5263; amino acids 128–271;
Fig. 1). The N-terminal domain of lysinSM1 (N-lysinSM1) exhibits
75% amino acid identity to the Pal lysin (accession number
O03979) of the pneumococcal bacteriophage Dp-1, and 74%
identity to the lysin (accession number Q8E0W3) of the prophage
lambdaSa1 of Streptococcus agalactiae [19,20]. The C terminus of
lysinSM1 (C-lysinSM1) contains a choline-binding domain homol-
ogous to that found in the pneumococcal LytA autolytic enzyme
(62% identity), which anchors the protein to PC residues present in
LTA or teichoic acids [19].
To assess whether lysinSMl demonstrated its predicted biological
activities, we first examined its binding to DEAE-cellulose, a property
that is a hallmark of choline-binding proteins [21]. LysinSM1,N -
lysinSM1,andC-lysinSM1wereexpressed individuallyin Escherichiacoli,
and lysates from these strains were applied to a DEAE-cellulose
column [16]. N-lysinSM1 failed to bind the matrix, with the protein
being detected in the wash volumes (Fig. 2A). In contrast, lysinSM1
and C-lysinSM1 were only eluted with
TM buffer containing 2%
choline chloride. Thus, lysinSM1 appears to be a choline-binding
protein, with this interaction being mediated by the C terminus.
We then examined whether purified lysinSM1 bound directly to PC
residues of LTA purified from S. pneumoniae HS0001 and S. mitis
SF100. Purified FLAGlysinSM1 was incubated with immobilized LTAs,
and binding was assessed by ELISA with anti-FLAG antibody. As
shown in Fig. 2B, lysinSM1 bound LTA from S. mitis SF100 and from
S. pneumoniae HS0001, both of which contain PC. Of note, binding
levels of lysinSM1 to these LTAs were comparable and concentration-
dependent. In contrast, little or no binding to LTA was detected from
strain HS0001-EA, which has no PC. C-lysinSM1 also bound LTA
from SF100 and HS0001, whereas N-lysinSM1 did not (Figure S1).
These results confirm that lysinSM1 interacts with the PC residues of
LTA, and that binding is mediated by the predicted choline-binding
domain within the C terminus.
As mentioned above, analysis of the predicted amino terminus
of lysinSM1 indicated that it encodes an amidase with g-D-
glutaminyl-L-lysin endopeptidase activity [20]. To assess its lytic
activity, we tested the bactericidal properties of lysinSM1 in vitro
(Fig. 2C). When compared with organisms treated with buffer
alone, exposure of S. pneumoniae HS0001 to lysinSM1 resulted in a
mean (6 S.D.) reduction of 5.0761.28 log10 CFU per ml
(P,0.05). LysinSM1 was also active against the SM1 host strain
SF100 and its isogenic variant, PS1006, though it only reduced
mean titers by 0.860.04 (P,0.05) and 1.6560.21 log10 CFU per
ml (P,0.05), respectively. No bactericidal activity was seen when
tested against Staphylococcus aureus, Streptococcus sanguinis, Streptococcus
pyogenes, or E. coli. Of note, neither purified N-lysinSM1 nor C-
lysinSM1 had bactericidal activity against strains HS0001 or SF100
(data not shown). Thus, lysinSM1 has lytic activity against PC
positive strains, such as S. mitis and S. pneumoniae, though the latter
Author Summary
The binding of bacteria to human platelets is thought to
be a central event in the development of endocarditis (a
life-threatening cardiovascular infection). We have previ-
ously found that platelet binding by Streptococcus mitis is
mediated by surface components encoded by a bacterio-
phage contained within the host bacterium. We now show
that lysin (an enzyme of bacteriophage origin) contributes
to platelet binding via its direct interaction with fibrinogen
on the platelet surface. Lysin bound to purified fibrinogen
in vitro, and this interaction specifically involved the Aa
and Bb chains of fibrinogen. Binding of lysin to the
Bb chain was further localized to a region within the
fibrinogen D fragment. Disruption of the gene encoding
lysin gene resulted in a significant reduction in binding to
fibrinogen by S. mitis, as well as a major reduction in
virulence, as measured by a rat model of endocarditis.
These results indicate that lysin is a multifunctional
protein, representing a new class of fibrinogen-binding
molecules. Lysin is localized to the bacterial surface via its
interaction with cell wall choline, where it then can bind
fibrinogen directly. Cell surface lysin apparently also
contributes to the development of endovascular infections
via its previously unrecognized fibrinogen binding activity.
Figure 1. Domain organization of lysinSM1 and its homologs. Domains of lysinSM1 are compared with its closest homologs, the lambdaSa1
phage lysin of Streptococcus agalacitae and the LytA autolysin of Streptococcus pneumoniae, using the NCBI BLAST search program. Levels of identity
between regions are indicated. Also shown are the alignments of the amino (N-lysinSM1) and carboxyl terminal (C-lysinSM1) truncated form of lysinSM1.
CBD: choline-binding domain. SH3b: putative bacterial cell wall-binding domain.
doi:10.1371/journal.ppat.1001047.g001
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PLoS Pathogens | www.plospathogens.org 2 August 2010 | Volume 6 | Issue 8 | e1001047Figure 2. Lysin binding to phosphocholine (PC) residue and its biological activity. (A) Binding of lysinSM1 and its truncated forms to DEAE-
cellulose. Samples were separated by SDS-PAGE and stained with Coomassie blue. M: MW standards; lane 1: whole cell extracts of E. coli expressing
indicated protein; lane 2: proteins not retained by DEAE cellulose column; lane 3: proteins eluted with 1.5 M NaCl - 0.1% choline chloride; lane 4:
proteins eluted with 2% choline chloride. Arrows indicate position of expressed proteins. (B) Binding of FLAGlysinSM1 to immobilized LTA from
Streptococcus pneumoniae (SpLTA), PC-negative pneumococci (SpLTA-EA), or Streptococcus mitis (SmLTA). Bars indicate the means (6 S.D.) of
triplicate results in a representative experiment. (C) Bactericidal activity of lysinSM1. Values shown are number of surviving bacteria after exposure to
lysinSM1 or buffer (mean 6 S.D.). * =P,0.05, compared with the same strain exposed to buffer alone.
doi:10.1371/journal.ppat.1001047.g002
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lysinSM1 requires its choline-binding domain, in addition to its
predicted amidase domain, for this activity.
Binding of recombinant lysinSM1 to human platelets
We have previously observed that disruption of the gene
encoding lysinSM1 resulted in a significant reduction in platelet
binding by S. mitis [16]. To assess whether lysinSM1 could interact
directly with human platelets, we evaluated the binding of
FLAGlysinSM1 to immobilized human platelets and to isolated
platelet membranes (Fig. 3A). FLAGlysinSM1 was incubated with
platelet monolayers or platelet membranes, and bound FLAGly-
sinSM1 was then detected with anti-FLAG antibody. When tested
by this approach, we found that FLAGlysinSM1 strongly interacted
with both whole platelets and platelet membranes in a concen-
tration-dependent manner. In contrast, no binding of FLAGly-
sinSM1was seen to wells coated with only a casein-based blocking
reagent (Western Blocking Reagent; Roche).
To identify the membrane receptor for lysinSM1, we assessed by
far Western blotting the binding of FLAGlysinSM1 to platelet
membranes that had undergone SDS-PAGE and transfer to
nitrocellulose (Fig. 3B). Although the platelet membrane extracts
contained numerous proteins, ranging in mass from 50 to
250 kDa, FLAGlysinSM1 bound only a small number of proteins.
The highest levels of binding were seen with two proteins of MW
65 kDa and 55 kDa, which were similar to the molecular masses
of the Aa and Bb chains of human fibrinogen (64 and 56 kDa),
respectively. To confirm that platelet membrane extracts con-
tained fibrinogen, the preparations were probed with antibodies
directed against the three major chains of fibrinogen (Aa,B b and
c). As shown Fig. 3B, each subunit of fibrinogen was present in the
membrane extracts. To directly confirm that lysinSM1 bound
fibrinogen on platelet membranes, we assessed whether lysinSM1
binding to immobilized platelet membranes was inhibited by anti-
human fibrinogen IgG. As shown in Fig. 3C, pre-treatment of
membranes with 30 or 100 mg/ml of anti-fibrinogen antibodies
significantly reduced subsequent lysin binding. These results
further indicate that fibrinogen is the principal component on
platelet membranes and that lysinSM1 is bound to platelet
membranes through it interaction with fibrinogen.
Binding of lysinSM1 to fibrinogen
Since fibrinogen is a key factor in the pathogenesis of infective
endocarditis, and because it is a receptor for some bacterial adhesins
[7,22,23,24,25,26], we further investigated the interaction of this
p r o t e i nw i t hl y s i n SM1.W ef i r s ta s s e s s e dt h eb i n d i n go ft h ei n c r e a s i n g
concentrations of FLAGlysinSM1 to human fibrinogen (3 mg/ml)
immobilized in microtiter wells. In control studies, no significant
binding of fibrinogen by FLAG-tagged alkaline phosphatase
(FLAGAP) was detected (Figure S2). In contrast, FLAGlysinSM1 showed
significant binding to immobilized fibrinogen, which increased in
direct proportion to the amount of protein applied (Fig. 4A). At
concentrations above 125 mg/ml FLAGlysinSM1,b i n d i n gr e a c h e da
plateau, indicating that it was saturated. In addition, the binding of
FLAGlysinSM1 to immobilized fibrinogen was effectively blocked by
both unlabeled lysinSM1 and fibrinogen (Fig. 4B). Similar levels of
lysin binding were seen with rat fibrinogen, the host used for our
subsequent virulence assays (Figure S3).
For some bacteria, binding to fibrinogen is dependent on
whether the protein is in solution or immobilized on a surface.
For example, Group A and G streptococci can bind both soluble
and immobilized forms of fibrinogen, whereas several oral
streptococci appear to bind only immobilized fibrinogen
[27,28,29]. To assess whether fibrinogen binding by lysinSM1
was phase-dependent, we reversed the binding conditions, such
that FLAGlysinSM1, untagged lysinSM1,a n dFLAGAP (all at 10 mg/
ml) were immobilized in microtiter wells, and probed with the
increasing concentration of fibrinogen in solution. Under these
conditions, fibrinogen was still found to bind lysinSM1 and
FLAGlysinSM1 comparably, whereas no significant binding to
FLAGAP was detected (Fig. 4C).
As noted above, we found that lysinSM1 bound two proteins
associated with platelet membranes that corresponded to the Aa
and Bb chains of fibrinogen. To confirm that lysinSM1 binds
specifically to these subunits, we assessed by far Western blotting
the interaction of lysinSM1 with purified human fibrinogen
(Fig. 4D). When separated by SDS-PAGE under reducing
conditions, fibrinogen appeared as three bands, having the
expected masses. When transferred to nitrocellulose and probed
with FLAGlysinSM1, binding could be detected to the Aa and Bb
chains only, confirming the results seen with platelet membranes.
Figure 3. Lysin binding to platelet monolayers and platelet membranes. (A) Immobilized human platelets or platelet membranes were
incubated with the indicated concentrations of purified FLAGlysinSM1, washed, and bound FLAGlysinSM1 was assessed by ELISA. Bars indicate the means
(6 S.D.) of triplicate data from a representative experiment. (B) LysinSM1 binding to platelet membrane proteins (far Western blotting). Proteins were
either stained with Coomassie blue (panel 1), or transferred to nitrocellulose membranes and probed with FLAGlysinSM1 (panel 2). Platelet membrane
proteins were probed with anti-fibrinogen Aa chain (panel 3), anti-fibrinogen Bb chain (panel 4), or anti-fibrinogen c chain (panel 5) polyclonal
antibodies. (C) Inhibition of FLAGlysinSM1 binding to platelet membranes by fibrinogen IgG polyclonal antibody. Immobilized platelet membranes were
incubated with the indicated concentrations of rabbit anti-fibrinogen IgG prior to testing for binding by FLAGlysinSM1 (5 mg/ml). Bars indicate the
means (6 S.D.) of triplicate results from a representative experiment. * =P,0.05, compared with no antibody treatment.
doi:10.1371/journal.ppat.1001047.g003
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The fibrinogen molecule is comprised of two subunits, each
containing three polypeptide chains (Aa,B b,a n dc;F i g .5 A ) .
Cleavage of fibrinogen with plasmin produces a series of fragments,
most notably the E fragment containing the central part of the
molecule, and the D fragment containing the terminal regions. To
further identify the domains of fibrinogen bound by lysinSM1,w e
examined the interaction of FLAGlysinSM1 to the D and E fragments.
When assessedby ELISA, FLAGlysinSM1showedhighlevelsofbinding
to immobilized fragment D, which were comparable to those seen
with whole fibrinogen (Fig. 5B). In contrast, no significant binding to
the E fragment was seen.
Purified fibrinogen fragment D contains three subunits,
each representing a part of the three major chains (a chain
fragment =15 kDa, b chain fragment =44.5 kDa, and c chain
fragment =42 kDa) (Fig. 5A). To further identify the subdomains
of fibrinogen bound by lysinSM1, purified fragment D was separated
under reducing conditions and transferred to a nitrocellulose
membrane. When assessed by far Western blotting, binding by
FLAGlysinSM1, was limited to the Bb chain component of fragment D
with no binding detected to the Aa chain (Fig. 5C). These data
indicate lysinSM1 binds a region contained within AA 134–461 of the
Bb chain. Of note, lysinSM1 bound the full-length Aa chain (Fig. 3B),
but not its D or E fragments (Fig. 5C), suggesting that the lysinSM1
binding to the Aachain requires the C terminus (AA 197–610).
LysinSM1 promotes the interaction of S. mitis SF100 with
fibrinogen
To assess the impact of lysin expression on bacterial binding to
fibrinogen, we compared the adherence of SF100 (WT) and PS1006
(Dlysin) to fibrinogen immobilized in microtiter wells. As shown in
Fig. 6A, SF100 had high levels of binding to immobilized fibrinogen,
Figure 4. Lysin-fibrinogen binding. (A) Binding of FLAGlysinSM1 to immobilized human fibrinogen. X-axis indicates concentration of FLAGlysinSM1
incubated with fibrinogen. (B) Inhibition of FLAGlysinSM1 binding to immobilized fibrinogen by unlabelled lysinSM1 or fibrinogen. The binding of
FLAGlysinSM1 (3 mg/ml) to immobilized fibrinogen was tested in buffer containing 0 to 1,000 mg/ml of lysinSM1 or fibrinogen. * =P,0.05, as compared
with 0 mg/ml. (C) Fibrinogen binding to immobilized FLAGlysinSM1, unlabelled lysinSM1,o rFLAGAP. Concentrations indicate amount of protein added.
Bars are the means (6 S.D.) of triplicate results from a representative experiment. (D) Binding of FLAGlysinSM1 to fibrinogen by far Western blotting.
Fibrinogen was separated by SDS-PAGE and stained with Coomassie blue (panel 1) or transferred to nitrocellulose and probed with FLAGlysinSM1
(panel 2). The three bands detected in panel 1 correspond to Aa,B b, c chains of fibrinogen. Numbers indicate molecular mass. Binding of FLAGlysinSM1
to the Aa and Bb chains was readily observed, but not to the c chain (panel 2).
doi:10.1371/journal.ppat.1001047.g004
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wells. PS1006 showed markedly reduced levels of binding, as
compared with the parent strain. For example, when tested with
wells coated with 30 mg/ml of fibrinogen, PS1006 had only
18.864.7% (mean 6 SD) of maximal binding, as compared with
89.7612.8% for SF100 (P,0.05, unpaired t-test). Complementation
of the lysin mutation in trans restored fibrinogen binding by PS1006
(Fig. 6B), thereby demonstrating that the loss of binding observed
with lysin disruption was not due to polar or pleiotropic effects.
The above results suggested that the binding to immobilized
fibrinogen by SF100 is mediated by lysinSM1 expressed on the
bacterial surface. To confirm that lysin was sufficient to mediate
fibrinogen binding, we next examined whether exogenous lysinSM1
could attach to the cell wall of PS1006 and restore binding. The
PC-negative strain SK598 served as a negative control. Each strain
was incubated with purified FLAGlysinSM1 at RT for 30 min. After
washing to remove nonspecifically bound protein, cell wall bound
FLAGlysinSM1 was extracted with 2% choline, and the amount of
FLAGlysinSM1 recovered was assessed by Western blotting. As
shown in Fig. 6C, exogenous FLAGlysinSM1 could readily be
detected in the cell wall extracts of PS1006, whereas no binding of
FLAGlysinSM1was observed with SK598.
Wethen assessed whether this interaction was sufficient to enhance
the binding of PS1006 to fibrinogen (Fig. 6D).PS1006 was suspended
in PBS containing a range of concentrations of purified lysinSM1 and
then tested for its binding to immobilized fibrinogen, as described
above. As expected, PS1006 incubated in PBS alone showed minimal
levels of binding to fibrinogen. This was not due to a loss of PblA and
PblB expression, since the pblA/pblB negative strain PS344 had levels
of fibrinogen binding that were similar to those of the parent strain.
Exposure of PS1006 to FLAGlysinSM1 increased fibrinogen binding in
a concentration-dependent manner. Indeed, 10 mgp e rm lo f
FLAGlysinSM1 was sufficient to restore PS1006 binding to levels
comparable to those seen with SF100.
Role of lysinSM1 in the pathogenesis of infective
endocarditis
To assess the impact of lysinSM1 on pathogenesis, we compared
the relative virulence of SF100, PS344 and PS1006 in a rat co-
Figure 5. Binding of FLAGlysinSM1 to immobilized fibrinogen fragments D and E. (A) Schematic diagram of human fibrinogen. The Aa,B b,
and c chains, major disulfide linkages, and plasmin cleavage sites are shown. (B) Indicated concentrations of FLAGlysinSM1 were incubated with
immobilized human fibrinogen, fibrinogen fragment D, or fragment E. Bound FLAGlysinSM1 was detected with anti-FLAG antibody. Bars indicate the
means (6 S.D.). (C) Fibrinogen fragment D was separated by SDS-PAGE under reducing conditions and stained with Coomassie blue (panel 1) or
transferred onto nitrocellulose membrane and incubated with FLAGlysinSM1 (5 mg/ml). The bound proteins were detected with anti-FLAG antibody
(Lane 2). Arrows indicate positions of Aa,B b, and c chain fragments. Numbers indicate molecular mass (kDa).
doi:10.1371/journal.ppat.1001047.g005
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compared SF100 with PS344 to confirm previous results obtained
in a rabbit model of infection [16]. As was observed with rabbits,
disruption of pblA and pblB was also associated with attenuated
virulence in rats, with PS344 having significantly reduced levels of
bacteria within all tissues (Table 1). Disruption of lysinSM1 also
produced a significant reduction in virulence. Rats co-infected
with SF100 and PS1006 had significantly lower densities of the
lysin mutant strain in vegetations (mean 6 SD =5.0761.50
log10 CFU/g) as compared with the parent strain (6.9161.35
log10 CFU/g; n=8, P=0.009). Densities of PS1006 were also
significantly reduced in kidneys (P=0.008) and spleens (P,0.001)
as compared with SF100. We then examined the relative impact
on virulence of abrogated PblA and PblB expression, versus loss of
lysin (Table 1). In animals co-infected with PS344 and PS1006,
titers of the latter mutant were significantly reduced in all tissues
examined, as compared with the former. In particular, the mean
densities of PS1006 within vegetations (6.5961.45 log10 CFU/g)
were significantly lower than those of PS344 (8.3260.76; n=8;
P=0.008), as were densities within kidneys (P=0.027) and spleens
(P=0.006). We then re-analyzed these data by comparing the
ratio of PS344 to PS1006 within tissues, with the CFU of each
strain normalized to the number of CFU within the inoculum
(competition index) (Figure S4). When assessed by this approach,
the levels of the lysinSM1 mutant PS1006 remained significantly
reduced in all tissues, as compared with PS344. Thus, lysinSM1
appears to be a significant virulence determinant in the setting of
infective endocarditis. Moreover, its role in pathogenesis is not due
solely to any effect it may have on PblA and PblB expression.
Instead, it appears to have an impact upon the development of
infective endocarditis independent of these other phage-encoded
proteins.
Discussion
The binding of pathogenic bacteria to platelets is thought to
play a key role in the pathogenesis of infective endocarditis. This
interaction may be important both for the initial attachment of
Figure 6. Lysin mediates binding of bacteria to fibrinogen. (A) 10
6 CFU of SF100 or PS1006 were incubated with wells pretreated with the
indicated concentrations of fibrinogen. Values represent percent of SF100 binding to wells treated with 300 mg/ml fibrinogen. (B) Complementation
of the lys mutant (PS1006) with the lys gene in trans assessed by measuring S. mitis binding to immobilized human fibrinogen. PS1959 (PS1006
complemented with lys) demonstrated significantly greater levels of binding (P,0.05) than PS1006 or PS2093 (PS1006 complemented with pDE123
control vector). Levels of fibrinogen binding by PS1959 were comparable to those seen with SF100 (P.0.05). (C) Binding of FLAGlysinSM1 to PS1006,
but not SK598. Bacteria were incubated with purified lysinSM1, and lysinSM1 bound to the cell wall was detected with anti-FLAG antibody. Lane C
contains purified lysinSM1 (0.2 mg/ml) as a positive control. (D) PS1006 was incubated with immobilized fibrinogen in the presence of indicated
concentration of purified FLAGlysinSM1 (mg/ml). Values represent percent of SF100 binding, and are the means of triplicate results from a representative
experiment. * =P,0.05 compared with SF100; # =P.0.05 compared with PS1006.
doi:10.1371/journal.ppat.1001047.g006
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formation of vegetations. Numerous endocarditis-associated
pathogens have been shown to bind platelets directly in vitro,
through a variety of mechanisms [3,4,7,8,25,30]. The ability to
bind platelets in vitro has been linked to virulence for several of
the most common endocarditis-associated species, including
Staphylococcus aureus, Streptococcus gordonii,a n dStreptococcus sanguinis
[5,31,32,33]. Previous work from our laboratory has shown that
platelet binding by S. mitis strain SF100 is mediated in part by
two proteins (PblA and PblB) encoded by the lysogenic
bacteriophage SM1 [16]. The functional localization of these
proteins to the cell surface requires the phage lysin (lysinSM1),
which permeabilizes the host organism, thereby permitting the
transport of PblA and PblB from the cytoplasm to the bacterial
surface, and their subsequent attachment to the cell wall [16].
During the course of these studies, we noted that disruption of
the gene encoding lysinSM1 reduced platelet binding in vitro more
profoundly than the loss of PblA and PblB localization,
indicating that lysin had a role in platelet binding beyond
facilitating PblA and PblB transport. It was unknown, however,
whether lysin itself could directly mediate binding, or rather, the
effects of lysin on bacterial permeability led to the surface
expression of other proteins (either phage or bacterial) that
could enhance platelet binding.
Our current results demonstrate that lysin can bind human
platelets directly through its interaction with fibrinogen. Purified
lysin was found to bind fibrinogen, regardless of whether the
proteins were in solution or immobilized. The binding of lysin with
fibrinogen also was saturable, consistent with a receptor-ligand
interaction. Lysin binding was restricted to the D fragment of the
Aa and Ab chains, further indicating that this is a specific process.
This interaction appears to be important for the binding of S. mitis
to fibrinogen, since disruption of the gene encoding lysin markedly
reduced fibrinogen binding by bacteria in vitro. The addition of
exogenous purified lysin to these mutants restored binding to WT
levels, confirming that lysin can directly mediate the interaction of
S. mitis with fibrinogen.
A number of other bacterial proteins have been shown to
bind fibrinogen, including the M protein and serum opacity
factor of Streptococcus pyogenes,F b s Ao fStreptococcus agalactiae,
SdrG of Staphylococcus epidermidis, and several proteins of
Staphylococcus aureus (clumping factors A and B, fibronectin
binding protein A) [4,22,25,30,34]. However, none of these
proteins exhibit any primary sequence homology with lysinSM1.
The staphylococcal autolysins Aaa and Aae do resemble
lysinSM1, in that they appear to have both enzymatic and
fibrinogen binding activities in vitro [35,36]. A search against
the SMART and Pfam databases indicates that collectively
these proteins belong to the NlpC/P60 superfamily of proteins,
containing their catalytic domain that are characteristic of this
group of proteins. However, the predicted catalytic activity of
lysinSM1 (amidase 5) is different from that autolysins Aaa and
Aae. LysinSM1 has no sequence similarity to either the Aaa or
Aae protein, and unlike these other proteins, it is a choline-
binding protein. Thus, lysin appears to be a multi-functional
protein that can mediate S. mitis binding to fibrinogen, in
addition to its role in the transit of the PblA and PblB proteins
to the cell surface.
LysinSM1 was also associated with increased virulence in a
rat model of infective endocarditis. When animals were co-
infected with the parent strain SF100 and the lysinSM1 mutant
PS1006, densities of the lysin mutant were significantly
reduced within vegetations, kidneys, and spleens, as compared
with the parent strain. Moreover, the virulence of PS1006 was
also attenuated, when compared with its pblA and pblB-
deficient isogenic variant, PS344. These results indicate that,
beyond its importance for PblA and PblB expression, lysin
contributes to virulence through a mechanism beyond its role
in the transport of these bacteriophage-encoded adhesins. It is
possible that there are other, unrecognized phage-encoded
virulence factors that require lysin for export or localization.
However, in view of the ability of lysin to bind fibrinogen
directly (both human and rat), and that fibrinogen binding has
been associated with virulence for several other adhesins
[37,38,39,40,41], it is likely that this interaction of lysin with
fibrinogen contributes to the pathogenesis of infective endo-
carditis by S. mitis. Given that lysin-fibrinogen binding
enhances bacterial adherence to platelets in vitro, and that
bacterium-platelet binding has been linked to virulence, it is
likely that lysin-mediated binding to platelets via fibrinogen is
an important pathogenetic interaction. However, it is also
possible that lysin mediates streptococcal binding to fibrinogen
on other surfaces, such as damaged endothelium. Finally, it is
conceivable that lysin contributes to virulence through other,
as yet unidentified interactions.
In summary, lysin is a novel fibrinogen-binding protein
encoded by a lysogenic bacteriophage of S. mitis.I na d d i t i o nt o
its expected role in cell wall degradation, lysin also appears to be
an adhesin mediating the attachment of this organism to human
platelets, through its interaction with cell wall PC, fibrinogen, and
the platelet membrane receptor for fibrinogen, glycoprotein
IIb/IIIa (Fig. 7). Lysin also appears to contribute significantly to
virulence, which could explain the persistence of certain
bacteriophages within their host organisms. Although induction
of the phage lytic cycle extracts a toll on host viability, in vivo this
may be more than offset by the enhanced virulence resulting from
Table 1. Impact of lysin expression on virulence in a rat model of infective endocarditis.
Strain pairs N Vegetations Kidneys Spleens
Mean ± S.D. (Log10
CFU/g) P
Mean ± S.D. (Log10
CFU/g) P
Mean ± S.D. (Log10
CFU/g) P
SF100
PS344 8
6.1960.84
5.3961.09 ,0.001
3.1060.91
2.2860.94 0.018
3.2060.56
2.2360.91 0.005
SF100
PS1006 12
6.9161.35
5.0761.50 0.009
3.6261.33
2.4061.35 0.008
3.5861.17
2.5061.41 ,0.001
PS344
PS1006 8
8.3260.76
6.5961.45 0.008
3.8960.77
2.9461.22 0.027
3.3460.74
2.2561.32 0.006
Bacterial densities within tissues 72 h after co-infection.
doi:10.1371/journal.ppat.1001047.t001
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crevicular fluid, lysin-fibrinogen binding may also contribute to
the colonization of oral surfaces by S. mitis [42,43]. Although we
do not know the exact prevalence of lysinSM1 homologs in other
organisms, recent studies of S. pneumoniae and Enterococcus faecalis
indicate that lysogenic bacteriophages encoding homologs of
PblA and PblB are often present within these species [44,45].
Since lysins are required for the phage life cycle, these findings
suggest that homologs of lysinSM1 may also be encoded by such
prophages. If so, then lysin binding to fibrinogen could prove to
be an important interaction for a range of Gram-positive
pathogens.
Materials and Methods
Ethics statement
Blood was obtained from healthy human volunteers, using a
protocol approved by the Committee on Human Research at the
University of California, San Francisco. All human studies were
conducted according to the principles expressed in the Declaration
of Helsinki. Written informed consent was obtained from all study
participants prior to their participation. All procedures involving
rats were approved by the Los Angeles Biomedical Research
Institute animal use and care committee, following the National
Institutes of Health guidelines for animal housing and care.
Reagents
N terminal Met-FLAG-alkaline phosphatase (FLAGAP) and
purified rat fibrinogen were purchased from Sigma-Aldrich.
Purified human fibrinogen and the fibrinogen fragment D and E
(produced by cleavage of fibrinogen with plasmin) were obtained
from Haematologic Technologies. Rabbit anti-human fibrinogen
polyclonal IgG was purchased from Innovative Research.
Cloning and expression of lysinSM1
Genomic DNA was isolated from SF100, using Wizard
Genomic DNA purification kits (Promega), according to the
manufacturer’s instructions. Polymerase chain reaction (PCR) was
performed with the primers listed in Table S2. To clone lys gene
into E. coli expression vector, PCR products were purified,
digested, and ligated into pET28FLAG to express FLAG-tagged
versions of full length lysinSM1 (amino acids [AA] 1–295), the
amino terminus of lysinSM1 (AA 1–158; N-lysinSM1), or the
carboxy terminus of lysinSM1 (AA 141–295; C- lysinSM1).
Untagged lysinSM1, C-lysinSM1, and His-tagged N-lysinSM1 (HisN-
lysinSM1) were cloned into pET22b(+) (Novagen). The plasmids
were then introduced to E. coli BL21(DE3) by transformation.
LysinSM1, FLAGlysinSM1, C-lysinSM1 and FLAGC-lysinSM1 were
purified with DEAE-cellulose columns, as described previously
[16]. FLAGN-lysinSM1 and HisN-lysinSM1 were purified by either
Ni-NTA (Promega) or anti-FLAG M2 agarose affinity chroma-
Figure 7. Model for the role of lysin in platelet binding. Phage lysin is exported through the holin pore and mounted on the bacterial surface
of the same or adjacent organisms through its interaction with PC residues. Lysin can then mediate platelet binding via its interaction with fibrinogen
and glycoprotein IIb/IIIa (GPIIb/IIIa), which is the principal fibrinogen receptor on platelets. Through its amidase activity, lysin can also permeabilize
the cell wall, permitting the release and surface expression PblA and PblB. These phage proteins also interact with platelets by binding the membrane
ganglioside GD3.
doi:10.1371/journal.ppat.1001047.g007
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instructions.
Deletion or complementation of the lysin gene (lys)
A gene replacement cassette was constructed by cloning the
chromosomal regions flanking lys upstream and downstream of the
cat gene in pC326 [16]. A 339 bp upstream segment was amplified
using primers KO4F and KO4R, and then digested with XhoI and
HindIII. A 513 bp downstream segment was amplified with
primers KO6F and KO6R, and then digested with EcoRI. The
upstream and downstream fragments were cloned sequentially into
the corresponding sites of pC326. The resulting plasmid, pKO-lys,
was introduced into SF100 by natural transformation as previously
described [17]. In brief, overnight SF100 cultures were diluted
100-fold in fresh THB supplemented with 20% heat-inactivated
horse serum, 200 ng/ml competence-stimulating peptide (CSP;
DWRISETIRNLIFPRRK), and 1 mg/ml of plasmid. Transfor-
mation mixtures were incubated 4 h at 37uC and then plated on
blood agar containing 5 mg chloramphenicol per ml. To
complement in trans the lys mutation in PS1006, lys was amplified
using primers 3206-XbaI and 5206-EcoRI and then cloned into the
streptococcal expression vector pDE123. This plasmid was derived
from pDC123 by replacing the chloramphenicol resistance marker
with an erythromycin resistance marker [46]. The resulting
plasmid, pDE-lys, was introduced into PS1006 by natural
transformation.
Strains and growth conditions
The bacteria and plasmids used in this study are listed in Table
S1. S. mitis strains were grown in Todd-Hewitt broth (Difco)
supplemented with 0.5% yeast extract (THY). PS344 (DORF47-
PblB::pVA891) and PS1006 (DlysinSM1) are isogenic variants of S.
mitis SF100, which is an endocarditis-associated clinical isolate
[16]. All three strains grow comparably well in vitro. S. pneumoniae
strains were grown in either a chemically defined medium (CDM;
JRH bioscience) [47] supplemented with 0.1% choline chloride, or
THY. S. pneumoniae HS0001 is a nonencapsulated pneumococcal
strain derived from the TIGR4 strain by deleting the capsule
synthesis locus as described previously [48]. S. pneumoniae HS0001-
EA is a PC-negative strain derived from HS0001 as described
previously [49]. Escherichia coli DH5a and BL21(DE3) strains were
grown at 37uC under aeration in Luria broth (LB; Difco).
Appropriate concentrations of antibiotics were added to the
media, if required.
Purification of lysinSM1 and C-lysinSM1 in DEAE-cellulose
Transformed E. coli BL21(DE3) cells were harvested by
centrifugation, washed and suspended in 50 mM Tris-maleate
(
TM) buffer (Sigma-Aldrich), pH 6.3. Cells were disrupted by
treatment with B-PER lysis solution (Pierce, Rockford, IL) and the
debris was removed by centrifugation at 4,000 rpm for 10 min at
4uC. Supernatants were loaded on a 2 ml DEAE-cellulose (Sigma-
Aldrich) column equilibrated with 50 mM
TM buffer, pH 6.3. The
column was washed with at least 3 volumes of 50 mM
TM buffer,
pH 6.3, containing 1.5 M NaCl and 0.1% choline chloride, until
no protein was detected in the eluent. The retained proteins were
then eluted with 50 mM
TM buffer, pH 6.3, containing 1.5 M
NaCl and 2% choline chloride. Recombinant protein was dialyzed
against PBS and then stored at 270uC.
Bactericidal assay
Early log phage (A600=0.5) bacteria were harvested by
centrifugation and suspended in PBS at approximately 10
8–
10
9 CFU/ml. Bacteria samples were then incubated with or
without 30 mg/ml of purified lysinSM1 at 37uC for 30 min.
Samples were serially diluted in PBS and plated onto blood agar,
to determine the number of surviving bacteria.
Isolation of platelet membranes
Platelet membranes were prepared by glycerol lysis and gradient
centrifugation, as previously described [50]. In brief, isolated
human platelets were lysed in 5 volumes of lysis buffer (8.5 mM
Tris-Cl, 96.5 mM NaCl, 85.7 mM glucose, 1 mM EDTA, 10 mM
EGTA [pH 7.4]) containing Complete Protease Inhibitor Cocktail
(Roche). The sample was centrifuged (5,9006 g, 10 min) to
remove unlysed platelets, and the supernatant was applied to a
sucrose step gradient (10 ml of 33% sucrose on 5 ml of 66%
sucrose in buffer). After ultracentrifugation (90 min, 63,0006 g,
4uC), the membranes were removed, dialyzed against PBS
containing 10% glycerol, and stored at 270uC.
Far western blot analysis
Samples were separated by electrophoresis through 4–12%
NuPAGE Bis-Tris gels (Invitrogen) and transferred onto nitrocel-
lulose membranes. The membrane were treated with a casein-
based blocking solution (Western Blocking Reagent; Roche) at
room temperature, and then incubated for 1 h with FLAGlysinSM1
(5 mg/ml) or purified human fibrinogen (1 mg/ml) suspended in
PBS-0.05% Tween 20 (PBS-T). The membranes were then
washed three times for 15 min in PBS-T, and bound probe
proteins were detected with mouse anti-FLAG monoclonal
antibody (Sigma-Aldrich) or rabbit anti-fibrinogen polyclonal
IgG antibody.
Lysin binding to platelet monolayers or platelet
membranes
Washed, fixed human platelets or purified platelet membranes
were immobilized in 96 well microtiter plates as described
previously [51]. To reduce non-specific adherence, the wells were
then treated with the casein-based blocking reagent for 1 h at
room temperature. The blocking solution was removed by
aspiration, and the wells were incubated with 0 to 100 mgo f
FLAGlysinSM1 in PBS for 1 h, at RT, followed by washing to
remove unbound protein. Bound FLAGlysinSM1 was detected by
ELISA with anti-FLAG antibody. For some studies, the wells
containing platelet membranes were pretreated with 0 to 100 mg/
ml of rabbit anti-fibrinogen antibody for 30 min, followed by
washing to remove unbound antibody. Binding by FLAGlysinSM1
(5 mg/ml) was then assessed as described above.
Binding of recombinant FLAGlysinSM1 to fibrinogen and
fibrinogen fragments
Rat fibrinogen (10 mg/ml), human fibrinogen, or human
fibrinogen D or E fragments (all 15 nM in PBS), were immobilized
in 96-well microtiter dishes by overnight incubation at 4uC. The
wells were washed twice with PBS and blocked with 300 mlo f
casein-based blocking solution for 1 h at room temperature. The
plates were washed three times with PBS, and a range of
FLAGlysinSM1 concentrations in PBS with Tween 20 (0.05%) were
added. The plates were then incubated for 2 h at 37uC. Unbound
protein was removed by washing with PBS, and plates were
incubated with mouse anti-FLAG antibodies for 1 h at 37uC.
Binding was assessed by ELISA, using HRP-conjugated rabbit
anti-mouse IgG, for 1 h at 37uC. FLAGAP (25–100 mg/ml) served
as a control for nonspecific binding.
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FLAGlysinSM1, untagged lysinSM1,o rFLAGAP (10 mg/ml in PBS)
were immobilized in 96 well microtiter plates, followed by
blocking of the wells with the casein blocking solution. The wells
were incubated with a range of human fibrinogen for 1 h at room
temperature, followed by washing. Bound fibrinogen was detected
by ELISA, using anti-human fibrinogen IgG.
Assay for lysinSM1 binding to bacterial cell walls
Cultures of PS1006 and S. mitis SK598 in the early log phage of
growth (A600=0.5) were harvested by centrifugation and suspend-
ed in PBS. The bacteria were incubated with purified FLAGly-
sinSM1 (0 to 10 mg/ml) for 30 min at room temperature. The
samples were washed twice with PBS to remove unbound
FLAGlysinSM1 and incubated with PBS-2% choline chloride to
elute choline-binding proteins from the cell walls, as described
previously [21]. Eluted cell wall proteins were harvested by
centrifugation and loaded onto SDS-PAGE. Cell wall bound
FLAGlysinSM1 was detected by western blotting with anti-FLAG
antibody.
Assay for the binding of SF100 to immobilized fibrinogen
Overnight cultures of S. mitis SF100 or its isogenic mutants
(PS1006 and PS344) were diluted 1:10 in fresh THY broth,
incubated for 1 h at 37uC, and then exposed to UV light
(l=312 nm) for 3 min, to induce the expression of the lysogenic
bacteriophage SM1. The cultures were then incubated at 37uC for
an additional 2 h, followed by harvesting by centrifugation. The
pellets were suspended in PBS, and adjusted to a concentration of
10
6 CFU/ml. One hundred microliters of each suspension were
added to wells that had been coated overnight with 30 mg/well of
fibrinogen in carbonate buffer. The plates were incubated at room
temperature for 1 h, and the wells were washed three times with
PBS to remove nonadherent bacteria. The wells were then treated
with 50 ml of trypsin (2.5 mg/ml) for 30 min at 37uC to release the
bound bacteria. The number of bound bacteria was determined by
plating serial dilutions of the recovered bacteria onto blood agar.
Lipoteichoic acid (LTA) purification
LTA was prepared from S. pneumoniae HS0001 and S. mitis
strains by organic solvent extraction and octyl-Sepharose chro-
matography, as previously described [52]. In brief, bacteria were
cultured at 37uC for 10 h in CDM with 0.1% choline chloride
(Fisher scientific Inc.). To purify PC negative LTA, S. pneumoniae
HS0001-EA was cultured for 16 h in CDM supplemented with
2% ethanolamine. Pelleted bacteria were suspended in 0.05 M
sodium acetate (pH 4.0) and lysed by sonication. After extraction
from the lysate with a chloroform and methanol mixture (1:0.9),
the LTA was adsorbed onto an octyl-Sepharose CL-4B (Sigma-
Aldrich) equilibrated in a mixture of 15% n-propanol and 0.05 M
sodium acetate (pH 4.7). The absorbed LTA was then eluted with
35% n-propanol in 0.05 M sodium acetate (pH 4.7).
Analysis of LTA structure
Purified LTA was analyzed by matrix-assisted laser desorption
ionization-time of flight (MALDI-TOF) mass spectrometry [52]
(Figure S5). In brief, 1 ml of a sample (1 mg/ml) and 1 ml of matrix
solution (0.5 M 2, 5-dihydroxybenzoic acid and 0.1% trifluor-
oacetic acid in methanol) were applied to a sample plate. After
drying, the sample was analyzed with a mass spectrometer
(Voyager Biospectrometry DE Pro workstation; PerSeptive
Biosystems). Purified LTA showed three major peaks that
corresponded to LTA with five, six, and seven repeating units,
respectively. The mass difference between the major peaks was
1299 or 1100 amu, corresponding to an oligosaccharide repeating
unit with two PC groups or two phosphoethanolamine groups
[52]. In addition, PC expression by strains HS0001 and SF100
was directly assessed by western blotting with anti-PC antibody
(TEPC-15; Sigma-Aldrich) [53] (Figure S6).
Rat model of infective endocarditis
The relative virulence of SF100 and its isogenic variants was
compared in a competition model of infective endocarditis, as
described previously [16,54]. In brief, Sprague-Dawley female rats
(250 to 300 g each) were first anesthetized with ketamine (35 mg/
kg) and xylazine (10 mg/kg). A sterile polyethylene catheter was
surgically placed across the aortic valve of each animal, such that
the tip was positioned in the left ventricle, to induce the formation
of sterile vegetations (nonbacterial thrombotic endocarditis). The
catheters were left in place throughout the study. Seven days post-
catheterization, the animals were infected intravenously with an
inoculum of 10
5 CFU containing a 1:1 mixture of a) SF100 and
PS344, b) SF100 and PS1006, or c) PS344 and PS1006. At 72 hr
post-infection, the rats were euthanized with thiopental (100 mg
IP). Animals were included in the final analysis only if the catheters
were correctly positioned across the aortic valve at the time of
sacrifice, and if macroscopic vegetations were visible. All cardiac
vegetations, as well as samples of the kidneys and spleens, were
harvested, weighed, homogenized in saline, serially diluted, and
plated onto 8% Todd Hewitt agar (62.5 mg/ml of chloramphen-
icol or 5 mg/ml of erythromycin) for quantitative culture. The
plates were cultured for 48 h at 37uC, and bacterial densities were
expressed as the log10 CFU per gram of tissue. Differences in
means were compared for statistical significance by the paired t-
test. The data were also analyzed by calculating a ‘‘competition
index,’’ which was defined as the ratio of the paired strains within
tissues for each animal, normalized by the ratio of organisms in the
inoculum. The mean of the log10 normalized ratios was tested
against the hypothesized ‘no effect’ mean value of 0, as described
previously, using a paired t-test, with P,0.05 as the threshold for
statistical significance [55].
Data analysis
Data expressed as means 6 standard deviations were compared
for statistical significance by the paired or unpaired t test, as
indicated.
Supporting Information
Figure S1 Binding of FLAGN-lysinSM1 or FLAGC-lysinSM1 to
immobilized LTA. A. Binding of FLAGN-lysinSM1 or FLAGC-
lysinSM1 to immobilized LTA from Streptococcus mitis SF100 (10 mg/
ml). B. Binding of FLAGC-lysinSM1 to immobilized LTA from
Streptococcus pneumoniae HS0001 (SpLTA-PC), which contains PC,
or LTA from Streptococcus pneumoniae HS0001-EA (SpLTA-EA),
which lacks PC. Bars indicate the means (6 S.D.) of triplicate
results in a representative experiment.
Found at: doi:10.1371/journal.ppat.1001047.s001 (0.22 MB TIF)
Figure S2 Binding of FLAGlysinSM1 or FLAG-tagged alkaline
phosphatase (FLAGAP) to immobilized fibrinogen. Indicated
concentrations of FLAGlysinSM1 or FLAGAP were incubated with
fibrinogen immobilized in microtiter wells, as described in the
[Methods] section. Bars indicate means 6 S.D
Found at: doi:10.1371/journal.ppat.1001047.s002 (0.14 MB TIF).
Figure S3 Binding of FLAGlysinSM1 to immobilized rat fibrino-
gen. Microtiter wells were coated with rat fibrinogen (10 mg/ml),
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FLAGlysinSM1. Binding was assessed as described for human
fibrinogen in the [Methods] section. Values shown are the means
(6 S.D.) of triplicate data from a representative experiment.
Found at: doi:10.1371/journal.ppat.1001047.s003 (0.13 MB TIF)
Figure S4 Impact of lysinSM1 expression on virulence. Endo-
carditis was produced in rats, using an inoculum containing SF100
and PS344, SF100 and PS1006, or PS344 and PS1006 at a 1:1
ratio. 72 h post infection, the animals were sacrificed, and
log10 CFU/g of tissue (vegetation, kidney, and spleen) for each
strain was determined by plating onto selective media. In vivo
competition index (CI) was calculated for each pair of organisms as
described in the [Methods]. Circles represent data from individual
animals. A CI below 10
0 indicates a competitive disadvantage for
A) PS344 versus PS344, B) PS1006 versus SF100, or C) PS1006
versus PS344.
Found at: doi:10.1371/journal.ppat.1001047.s004 (0.20 MB TIF)
Figure S5 Structural analysis of lipoteichoic acid by MALDI-
TOF mass spectrometry. A. Biochemical structure of S. mitis and S.
pneumoniae LTA. B. Mass spectra of S. pneumoniae HS0001 LTA.
Peaks at m/z 8572, 9872, and 11171 indicate LTA molecules with
6, 7, and 8 repeating units. C. Mass spectra of S. mitis SF100 LTA.
Peaks at m/z 7273, 8573, and 9872 indicate LTA molecules with
6, 7, and 8 repeating units. Due to composition of lipid tails, each
peak has at least three satellite peaks that differ from the major
peak by 26–28 AMU.
Found at: doi:10.1371/journal.ppat.1001047.s005 (0.30 MB TIF)
Figure S6 Detection of LTA phosphocholine (PC) residues.
Samples (1 mg) were separated by electrophoresis through 4–12%
NuPAGE Bis-Tris gels (Invitrogen) and transferred onto nitrocel-
lulose membranes. LTA were detected with mouse anti-PC
monoclonal antibody (TEPC-15; Sigma-Aldrich).
Found at: doi:10.1371/journal.ppat.1001047.s006 (0.34 MB TIF)
Table S1 Strains and plasmids
Found at: doi:10.1371/journal.ppat.1001047.s007 (0.06 MB
DOC)
Table S2 Primers.
Found at: doi:10.1371/journal.ppat.1001047.s008 (0.05 MB
DOC)
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